Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
0.2616
-0.0181 (-6.47%)
At close: Jun 27, 2025, 4:00 PM
0.2699
+0.0083 (3.17%)
After-hours: Jun 27, 2025, 7:47 PM EDT
Leap Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
10.84M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LPTX News
- 5 days ago - Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives - PRNewsWire
- 6 weeks ago - Leap Therapeutics Reports First Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting - PRNewsWire
- 2 months ago - Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer - PRNewsWire
- 3 months ago - Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript - Seeking Alpha
- 3 months ago - Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - Benzinga
- 3 months ago - Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 3 months ago - Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study - PRNewsWire